Laidlaw Reiterates Buy Rating on IN8bio Inc. (INAB)

Laidlaw analyst Yale Jen reiterated a Buy rating and $7.50 price target on IN8bio Inc. (NASDAQ: INAB).

The analyst comments "Over the weekend, INAB presented an update of INB-200 in glioblastoma (GBM) Phase I study results at the ASCO meeting. Our takeaways are that although the results were incremental, they nevertheless demonstrated the consistency of INB-200 treatment effect measured over a longer period. This outcome, in our opinion, bodes well for the outlook of the ongoing autologous INB-400 study, while we wait for some information to be available at the upcoming SNO meeting in 4Q24."

For an analyst ratings summary and ratings history on IN8bio Inc. click here. For more ratings news on IN8bio Inc. click here.

Shares of IN8bio Inc. closed at $1.19 yesterday.

You May Also Be Interested In

• Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
• Target (TGT) PT Raised to $146 at Piper Sandler
• Deere (DE) PT Lowered to $570 at JPMorgan Ahead of Earnings